These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 30506623)

  • 1. Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: Establishing baseline values.
    Leino AD; King EC; Jiang W; Vinks AA; Klawitter J; Christians U; Woodle ES; Alloway RR; Rohan JM
    Am J Transplant; 2019 May; 19(5):1410-1420. PubMed ID: 30506623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No Apparent Influence of Nonadherence on Tacrolimus Intrapatient Variability in Stable Kidney Transplant Recipients.
    Gokoel SRM; Zwart TC; Moes DJAR; van der Boog PJM; de Fijter JW
    Ther Drug Monit; 2020 Oct; 42(5):702-709. PubMed ID: 32941396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients.
    Seibert SR; Schladt DP; Wu B; Guan W; Dorr C; Remmel RP; Matas AJ; Mannon RB; Israni AK; Oetting WS; Jacobson PA
    Clin Transplant; 2018 Dec; 32(12):e13424. PubMed ID: 30318646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients.
    Vanhove T; Vermeulen T; Annaert P; Lerut E; Kuypers DRJ
    Am J Transplant; 2016 Oct; 16(10):2954-2963. PubMed ID: 27013142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between medication adherence and intrapatient variability in tacrolimus concentration among stable kidney transplant recipients.
    Ko H; Kim HK; Chung C; Han A; Min SK; Ha J; Min S
    Sci Rep; 2021 Mar; 11(1):5397. PubMed ID: 33686160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate- or prolonged-release tacrolimus.
    Vondrak K; Parisi F; Dhawan A; Grenda R; Webb NJA; Marks SD; Debray D; Holt RCL; Lachaux A; Kelly D; Kazeem G; Undre N
    Clin Transplant; 2019 Oct; 33(10):e13698. PubMed ID: 31436896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus Intrapatient Variability on Graft Outcomes in Adherent Renal Transplantation Patients: A Cross-Sectional Study.
    Nafar M; Keshtkari S; Ziaie S; Firouzan A; Borumandnia N; Dalili N; Poorrezagholi F; Samadian F; Samavat S
    Iran J Kidney Dis; 2024 May; 18(3):187-194. PubMed ID: 38904339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrolimus variability is associated with de novo donor-specific antibody development in pediatric renal transplant recipients.
    Solomon S; Colovai A; Del Rio M; Hayde N
    Pediatr Nephrol; 2020 Feb; 35(2):261-270. PubMed ID: 31732803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus.
    Shihab F; Qazi Y; Mulgaonkar S; McCague K; Patel D; Peddi VR; Shaffer D
    Am J Transplant; 2017 Sep; 17(9):2363-2371. PubMed ID: 28141897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of tacrolimus intra-patient variability on kidney transplant outcomes according to pre-transplant immunological risk.
    Kim EJ; Kim SJ; Huh KH; Kim BS; Kim MS; Kim SI; Kim YS; Lee J
    Sci Rep; 2021 Jun; 11(1):12114. PubMed ID: 34108576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late intra-patient tacrolimus trough level variability as a major problem in kidney transplantation: A Collaborative Transplant Study Report.
    Süsal C; Döhler B
    Am J Transplant; 2019 Oct; 19(10):2805-2813. PubMed ID: 30859672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of converting adult kidney transplant recipients with high tacrolimus variability from twice daily immediate release tacrolimus to once daily LCP-Tacrolimus.
    Taber DJ; Bartlett F; Patel N; Sprague T; Patel S; Newman J; Andrade E; Rao N; Salas MAP; Casey M; Dubay D; Rohan V
    Clin Transplant; 2023 May; 37(5):e14941. PubMed ID: 36809653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Failure of Calcineurin Inhibitor (Tacrolimus) Weaning Randomized Trial in Long-Term Stable Kidney Transplant Recipients.
    Dugast E; Soulillou JP; Foucher Y; Papuchon E; Guerif P; Paul C; Riochet D; Chesneau M; Cesbron A; Renaudin K; Dantal J; Giral M; Brouard S
    Am J Transplant; 2016 Nov; 16(11):3255-3261. PubMed ID: 27367750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based With Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation.
    Shuker N; Bouamar R; van Schaik RH; Clahsen-van Groningen MC; Damman J; Baan CC; van de Wetering J; Rowshani AT; Weimar W; van Gelder T; Hesselink DA
    Am J Transplant; 2016 Jul; 16(7):2085-96. PubMed ID: 26714287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns in Tacrolimus Variability and Association with
    Piburn KH; Sigurjonsdottir VK; Indridason OS; Maestretti L; Patton MV; McGrath A; Palsson R; Gallo A; Chaudhuri A; Grimm PC
    Clin J Am Soc Nephrol; 2022 Aug; 17(8):1194-1203. PubMed ID: 35882506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study.
    Harland RC; Klintmalm G; Jensik S; Yang H; Bromberg J; Holman J; Kumar MSA; Santos V; Larson TJ; Wang X
    Am J Transplant; 2020 Jan; 20(1):159-171. PubMed ID: 31509331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploratory Analysis of the Impact of an mHealth Medication Adherence Intervention on Tacrolimus Trough Concentration Variability: Post Hoc Results of a Randomized Controlled Trial.
    McGillicuddy JW; Chandler JL; Sox LR; Taber DJ
    Ann Pharmacother; 2020 Dec; 54(12):1185-1193. PubMed ID: 32506922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles.
    Oetting WS; Schladt DP; Guan W; Miller MB; Remmel RP; Dorr C; Sanghavi K; Mannon RB; Herrera B; Matas AJ; Salomon DR; Kwok PY; Keating BJ; Israni AK; Jacobson PA;
    Am J Transplant; 2016 Feb; 16(2):574-82. PubMed ID: 26485092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation.
    Taber DJ; Su Z; Fleming JN; McGillicuddy JW; Posadas-Salas MA; Treiber FA; Dubay D; Srinivas TR; Mauldin PD; Moran WP; Baliga PK
    Transplantation; 2017 Dec; 101(12):2931-2938. PubMed ID: 28658199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal Function in De Novo Liver Transplant Recipients Receiving Different Prolonged-Release Tacrolimus Regimens-The DIAMOND Study.
    TruneČka P; Klempnauer J; Bechstein WO; Pirenne J; Friman S; Zhao A; Isoniemi H; Rostaing L; Settmacher U; Mönch C; Brown M; Undre N; Tisone G;
    Am J Transplant; 2015 Jul; 15(7):1843-54. PubMed ID: 25707487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.